Axis Spine Technologies has brought together an expert team to develop our products and bring them to market.
Peter Dines is Chief Operating Officer of Mercia Asset Management PLC, a leading UK investment company. Peter joined the board of Axis Spine after co-founding the company with seed investment via the Mercia EIS funds.
In addition to Axis Spine, he is on the board of Mercia portfolio companies Locate Bio, Native Antigen, Concepta PLC and Sense Biodetection and is a co-founder of C7 Health, a diagnostic healthtech provider.
Peter has a wealth of spine experience having been the CEO of UK medical device company Surgicraft, responsible for developing and launching the first generation standalone STALIF® before spinning out Surgi C™ which he grew over five years to be the UK’s leading spinal distribution business where he successfully exited in 2012.
Ted Davis is the President & CEO of Active Implants, LLC., a sports medicine company developing and commercializing the NUsurface® Meniscus Implant. Prior to joining the Active Implants Board in 2016, he led MicroPort Orthopedics, Inc. from its establishment in 2014 through September 2015 following MicroPort Scientific’s acquisition of Wright Medical Technology, Inc.’s global OrthoRecon business.
Ted was President of Wright’s OrthoRecon division from November 2012 until its divestiture and previously led Wright’s Corporate Development, Research and Development and Business Development functions having originally joined Wright in December 2006. During his tenure at Wright/MicroPort, Ted helped establish three spin-outs of non-core technologies. Prior to joining Wright, Ted spent 10 years in the life sciences venture capital field, where he served on various boards of privately held medical device and biotechnology companies, most recently as a Partner with MB Venture Partners (MBVP) and previously with Vector Fund Management (VFM). Ted began his career in the healthcare management consulting and pharmaceutical industries.
Ted received a Bachelor of Engineering degree in Biomedical Engineering from Vanderbilt University and an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University. In addition to Axis Spine Technologies, he currently serves on the Board of Directors for Active Implants, LLC and SIBone, Inc.
Lucy Singah joined Axis Spine Technologies in May 2020 as Consultant FD, and brings over 10 years’ experience from leading pharmaceutical giant GlaxoSmithKline plc where she held a number of finance leadership roles. Lucy joined the M&A team and completed strategic deals including establishing a Joint Venture with Pfizer to create the HIV specialist company ViiV Healthcare. She then moved to the Group’s Investor Relations team, working closely with the Group CFO, and external investor and analyst community.
Lucy then became the Finance Director for the Head of Procurement with oversight of £14bn external spend, and latterly the Head of Oral and Skin Care in the Consumer business with revenues of £3.5bn.
Lucy is a member Institute of Chartered Accountants of Scotland qualifying in 2006 with Ernst & Young Transaction Advisory teams. Lucy worked across a variety of Corporate and Private Equity clients in Industrial and Consumer industries. She graduated from the University of Nottingham with BA Management Studies.